KVP Capital Advisors, LP — 13F Holdings & Portfolio

CIK 1858198 · latest 13F-HR filed 2026-08-13

KVP Capital Advisors, LP manages $136.2M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PRAX (10.54%), WHWK (7.28%), ERAS (6.12%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 6 new positions and exited 3; 18 existing positions rose in reported value and 7 fell.

AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.

Loading holdings…
AUM
$136.2M

Long-equity book

Holdings
35

Distinct positions

Period
2026-06-30

Filed 2026-08-13

Q/Q Activity
+6 / −3 / ↑18 / ↓7

vs 2026-03-31

Portfolio charts

Latest quarter's book, what changed, and how the portfolio has evolved across filings.

Portfolio map

Q2 26

Box size = position value; colour = change in share count vs the prior quarter (green added, red trimmed, blue new). Rows split across managers or share classes are combined. Click a box for the stock.

Sector mix

% of 13F value

Sectors from each company's SIC code; funds and ETFs grouped separately.

Biggest buys and sells

Q1 26 → Q2 26

Estimated from the change in shares held × the quarter-end price, so price moves alone don't count as buying. New and exited positions are included.

13F assets and positions

3 quarters

Total reported 13F value (bars) and number of positions (line) each quarter. Value changes include market moves.

Top positions over time

reported value

The eight largest current positions, valued at each quarter end.

Concentration

top 10 = 57.4%

Cumulative share of the portfolio held in the largest N positions.

Firm Profile & Key People

As of the firm’s regulatory filing dated Jun 29, 2026.

Assets Under Management
$220.9M
Discretionary
$123.1M
Employees
3
Accounts
2
Phone
(415) 875-7777
Name Title / Status Ownership Type
CASTELEIN, CALEY, MCNEILL ControlMANAGING DIRECTOR / LIMITED PARTNER
since Nov 2014
75% or moreIndividual
CASTELEIN, CALEY, MCNEILL ControlMANAGING DIRECTOR / LIMITED PARTNER
since Nov 2014
75% or moreIndividual
JENSEN, ANDREW, IRVING ControlCHIEF FINANCIAL OFFICER
since Nov 2014
10–25%Individual
JENSEN, ANDREW, IRVING ControlCHIEF FINANCIAL OFFICER
since Nov 2014
10–25%Individual
KVP CAPITAL ADVISORS, LLC ControlGENERAL PARTNER
since Nov 2014
Less than 5%Domestic Entity
KVP CAPITAL ADVISORS, LLC ControlGENERAL PARTNER
since Nov 2014
Less than 5%Domestic Entity
GUARINO, PETER, ROSERIOCHIEF COMPLIANCE OFFICER
since Jun 2026
Less than 5%Individual
GUARINO, PETER, ROSERIOCHIEF COMPLIANCE OFFICER
since Jun 2026
Less than 5%Individual
CASTELEIN, CALEY, MCNEILL Control
Indirect owner via KVP CAPITAL ADVISORS, LLC
OWNER
since Nov 2014
75% or moreIndividual
CASTELEIN, CALEY, MCNEILL Control
Indirect owner via KVP CAPITAL ADVISORS, LLC
OWNER
since Nov 2014
75% or moreIndividual
Ownership & leadership changes · 9 filings with changes since Jan 2, 2015

From the firm’s regulatory filings, newest first. Dates are filing dates: a filing that no longer lists someone does not say when they left.

Jun 29, 2026 filing
  • AddedGUARINO, PETER, ROSERIO · CHIEF COMPLIANCE OFFICER · Less than 5%
  • ChangedCASTELEIN, CALEY, MCNEILL · title MANAGING DIRECTOR / LIMITED PARTNER → LIMITED PARTNER / MANAGING DIRECTOR / MANAGING DIRECTOR / LIMITED PARTNER
  • ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER/ CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER
Mar 29, 2023 filing
  • ChangedJENSEN, ANDREW, IRVING · ownership 5–10% → 10–25%
Aug 7, 2020 filing
  • ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER / MANAGING DIRECTOR / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → MANAGING DIRECTOR / LIMITED PARTNER
  • ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER/ CHIEF COMPLIANCE OFFICER
Mar 30, 2020 filing
  • No longer listedDALAL, ANUPAM, AKSHAY · MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) · 10–25% · control person · listed since Nov 2014
Mar 28, 2019 filing
  • ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → LIMITED PARTNER / MANAGING DIRECTOR / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
  • ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
  • ChangedKVP CAPITAL ADVISORS, LLC · title GENERAL PARTNER (KVP CAPITAL ADVISORS, LP) → GENERAL PARTNER
Mar 30, 2017 filing
  • ChangedCASTELEIN, CALEY, MCNEILL · indirect via KVP CAPITAL ADVISORS, LLC: ownership 25–50% → 75% or more
Aug 26, 2016 filing
  • No longer listedDALAL, ANUPAM, AKSHAY · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person · listed since Nov 2014
  • ChangedCASTELEIN, CALEY, MCNEILL · ownership 25–50% → 75% or more
  • ChangedDALAL, ANUPAM, AKSHAY · title LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC); ownership 25–50% → 10–25%
Mar 29, 2016 filing
  • ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC) → CHIEF FINANCIAL OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
May 20, 2015 filing
  • ChangedCASTELEIN, CALEY, MCNEILL · title LIMITED PARTNER → LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
  • ChangedDALAL, ANUPAM, AKSHAY · title LIMITED PARTNER → LIMITED PARTNER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC)
  • ChangedJENSEN, ANDREW, IRVING · title CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER → CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER (KVP CAPITAL ADVISORS, LP) / MANAGING MEMBER (KEARNY VENTURE CAPITAL II, LLC); ownership Less than 5% → 5–10%
  • ChangedKVP CAPITAL ADVISORS, LLC · title GENERAL PARTNER → GENERAL PARTNER (KVP CAPITAL ADVISORS, LP)
Jan 2, 2015 filing (earliest on record)
  • ListedCASTELEIN, CALEY, MCNEILL · LIMITED PARTNER · 25–50% · control person
  • ListedCASTELEIN, CALEY, MCNEILL · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person
  • ListedDALAL, ANUPAM, AKSHAY · LIMITED PARTNER · 25–50% · control person
  • ListedDALAL, ANUPAM, AKSHAY · OWNER · 25–50% · indirect via KVP CAPITAL ADVISORS, LLC · control person
  • ListedJENSEN, ANDREW, IRVING · CHIEF FINANCIAL OFFICER AND CHIEF COMPLIANCE OFFICER · Less than 5% · control person
  • ListedKVP CAPITAL ADVISORS, LLC · GENERAL PARTNER · Less than 5% · control person

Quarter-over-quarter changes

Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.

KVP Capital Advisors, LP Holdings (2026-06-30)

Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).

# Issuer Symbol CUSIP Value Weight Shares Type
1 PRAXIS PRECISION MEDICINES I PRAX 74006W207 $14.4M 10.54% 42,900 SH
2 WHITEHAWK THERAPEUTICS INC WHWK 00032Q104 $9.9M 7.28% 2,165,997 SH
3 ERASCA INC ERAS 29479A108 $8.3M 6.12% 455,000 SH
4 TREVI THERAPEUTICS INC TRVI 89532M101 $7.7M 5.67% 414,000 SH
5 SUTRO BIOPHARMA INC STRO 869367201 $7.5M 5.52% 226,575 SH
6 TANGO THERAPEUTICS INC TNGX 87583X109 $7.2M 5.28% 230,264 SH
7 MBX BIOSCIENCES INC MBX 55287L101 $6.7M 4.92% 121,524 SH
8 PROTAGONIST THERAPEUTICS INC PTGX 74366E102 $6.5M 4.77% 53,000 SH
9 EDGEWISE THERAPEUTICS INC EWTX 28036F105 $5.4M 3.97% 133,000 SH
10 TANDEM DIABETES CARE INC TNDM 875372203 $4.5M 3.33% 301,000 SH
11 DISC MEDICINE INC IRON 254604101 $4.3M 3.13% 58,250 SH
12 SAVARA INC SVRA 805111101 $3.7M 2.74% 605,280 SH
13 ARRIVENT BIOPHARMA INC AVBP 04272N102 $3.5M 2.60% 102,000 SH
14 INSMED INC INSM 457669307 $3.0M 2.23% 28,497 SH
15 ACHIEVE LIFE SCIENCES INC QUIT 004468500 $3.0M 2.22% 462,355 SH
16 IDEAYA BIOSCIENCES INC IDYA 45166A102 $3.0M 2.18% 79,700 SH
17 OCULAR THERAPEUTIX INC OCUL 67576A100 $2.9M 2.16% 300,000 SH
18 AXSOME THERAPEUTICS INC. AXSM 05464T104 $2.9M 2.16% 12,000 SH
19 DESIGN THERAPEUTICS INC DSGN 25056L103 $2.7M 1.96% 185,000 SH
20 UNITED THERAPEUTICS CORP DEL UTHR 91307C102 $2.6M 1.89% 4,750 SH
21 SCHOLAR ROCK HLDG CORP SRRK 80706P103 $2.5M 1.82% 45,000 SH
22 IMMIX BIOPHARMA INC IMMX 45258H106 $2.4M 1.74% 230,423 SH
23 VIRIDIAN THERAPEUTICS INC VRDN 92790C104 $2.3M 1.69% 125,000 SH
24 MINERALYS THERAPEUTICS INC MLYS 603170101 $2.3M 1.67% 84,168 SH
25 BRIGHT MINDS BIOSCIENCES INC DRUG 10919W405 $2.2M 1.64% 31,813 SH
26 TRAVERE THERAPEUTICS INC TVTX 89422G107 $2.2M 1.63% 39,000 SH
27 ZURA BIO LTD ZURA G9TY5A101 $2.2M 1.62% 373,128 SH
28 ARTIVA BIOTHERAPEUTICS INC ARTV 04317A107 $1.9M 1.42% 200,000 SH
29 NEKTAR THERAPEUTICS NKTR 640268306 $1.9M 1.38% 26,900 SH
30 COMPASS THERAPEUTICS INC CMPX 20454B104 $1.7M 1.24% 771,000 SH
31 CABALETTA BIO INC CABA 12674W109 $1.6M 1.15% 505,431 SH
32 VERA THERAPEUTICS INC VERA 92337R101 $1.4M 1.03% 32,700 SH
33 EVOLUS INC EOLS 30052C107 $1.0M 0.76% 150,000 SH
34 CELCUITY INC CELC 15102K100 $418.5K 0.31% 4,000 SH
35 VYNE THERAPEUTICS INC VYNE 92941V308 $325.7K 0.24% 500,551 SH
Filing History
Period Filed AUM Holdings Accession
2026-06-30 2026-08-13 $136.2M 35 0001104659-26-095988
2026-03-31 2026-05-13 $133.9M 32 0001104659-26-060329
2025-12-31 2026-02-18 $103.3M 27 0001104659-26-016901
Filer Information
Address
4 EMBARCADERO CENTER
SUITE 2100
SAN FRANCISCO, CA 94111
Phone
(415) 875-7777
Filing Manager
KVP Capital Advisors, LP
SAN FRANCISCO, CA
Signatory
Andrew Jensen
Chief Financial Officer